Administration of beta blockers in patients with newly diagnosed multiple myeloma may be associated with a reduced risk of cancer-specific death.
Thalidomide and lenalidomide are equivalent with respect to survival outcomes in patients with multiple myeloma.
The US FDA has granted approval for additional indications for daratumumab for the treatment of patients with multiple myeloma who have received prior therapies.
A panel of International Myeloma Working Group members presents their review of current data on the potential host-, disease-, and treatment-related risk factors associated with the development of second primary malignancies in patients with multiple myeloma.
In this single-center, open-label, phase 2b trial, researchers determined if adding vorinostat to lenadolimide and dexamethasome would improve outcomes for patients with multiple myeloma refractory to lenalidomide.
In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.
Amgen talks about its collaboration with Janssen Biotech Inc on clinical trials that assess the combination of carfilzomib (Kyprolis) with daratumumab (Darzalex) in patients with multiple myeloma.
Results of this data analysis demonstrate the relationship between treatment facility volume and all-cause mortality among patients with multiple myeloma.
The phase 3 PANORAMA 1 trial previously demonstrated that panobinostat plus bortezomib and dexamethasone significantly prolonged progression-free survival vs bortezomib and dexamethasone alone. Final overall survival analysis is presented.
Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.
The combination of ixazomib and dexamethasone is clinically active and well tolerated in patients with relapsed multiple myeloma not refractory to bortezomib.
A longer duration of lenalidomide maintenance therapy after autologous HSCT may improve progression-free and overall survival in patients with multiple myeloma.
Antibacterial prophylaxis with the flouroquinolone, ciprofloxacin, substantially reduced the risk of bacteremia and neutropenic fever in patients with multiple myeloma or lymphoma undergoing high-dose chemotherapy and auto-HSCT.
Minimal residual disease (MRD) negativity after treatment is associated with prolonged overall survival in patients with newly diagnosed multiple myeloma.
Researchers have determined the risk of infection for immunomodulatory drug-based therapy and proteasome inhibitor-based therapy with respect to treatment phase in patients with multiple myeloma.
Daratumumab plus bortezomib and dexamethasone improves progression-free survival in multiple myeloma.
Daratumumab plus lenalidomide and dexamethasone resulted in rapid, deep, durable responses in patients with multiple myeloma.
Sociodemographic factors, not race or ethnicity, impact survival of younger patients with multiple myeloma.
Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple MyelomaAugust 16, 2016
The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).
A family history of lymphoproliferative disorders is not a risk factor for progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma.
Treatment with daratumumab, lenalidomide, and dexamethasone (DRd) may be superior to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.
Increasing body mass index (BMI) allows growth and progression of disease in patients with multiple myeloma, a recently published study has shown.
[Blood and Lymphatic Cancer: Targets and Therapy] This research reviews clinical symptoms, diagnosis, and risk factors of peripheral neuropathy, particularly dealing with the incidence, mechanisms, and management of TiPN and BiPN.
Researchers discovered that changes in the bone marrow needed for multiple myeloma to grow have already taken hold in patients with MGUS.
Assessment and Monitoring of Patients Receiving Chemotherapy for Multiple Myeloma: Strategies to Improve OutcomesJuly 01, 2016
[Blood and Lymphatic Cancer: Targets and Therapy] This research reviews updates in the diagnosis and management of multiple myeloma, and provides for assessment and monitoring strategies for patients receiving chemotherapy for multiple myeloma.
Response to the human CD38-directed monoclonal antibody daratumumab is significantly associated with CD38 expression on the tumor cells in patients with multiple myeloma, per a recent study.
Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple MyelomaJune 15, 2016
Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.
A post-hoc analysis of the Phase 3 ASPIRE study indicates that treatment combining carfilzomib with lenalidomide and dexamethasone extended survival time for patients with multiple myeloma.
A third clinical trial is beginning for phase I testing of SurVaxM, a cancer vaccine. This trial tests for safety and effectiveness of the vaccine in combination with lenalidomide as maintenance therapy for adults with multiple myeloma.
Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple MyelomaJune 06, 2016
Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Loperamide Regimen May Reduce Diarrhea in Neratinib-treated Patients
- PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab
- Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer
- Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|